Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.

Heiber JF, Xu XX, Barber GN.

Chin J Cancer. 2011 Dec;30(12):805-14. doi: 10.5732/cjc.011.10205. Epub 2011 Nov 4. Review.

2.

Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.

Capo-chichi CD, Yeasky TM, Heiber JF, Wang Y, Barber GN, Xu XX.

Gynecol Oncol. 2010 Feb;116(2):269-75. doi: 10.1016/j.ygyno.2009.10.086. Epub 2009 Nov 22.

3.

Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.

Ben Yebdri F, Van Grevenynghe J, Tang VA, Goulet ML, Wu JH, Stojdl DF, Hiscott J, Lin R.

Mol Ther. 2013 Nov;21(11):2043-53. doi: 10.1038/mt.2013.187. Epub 2013 Aug 28.

4.

Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.

Le Boeuf F, Niknejad N, Wang J, Auer R, Weberpals JI, Bell JC, Dimitroulakos J.

Int J Cancer. 2012 Aug 1;131(3):E204-15. doi: 10.1002/ijc.27404. Epub 2012 Jan 11.

5.

Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.

Liu YP, Steele MB, Suksanpaisan L, Federspiel MJ, Russell SJ, Peng KW, Bakkum-Gamez JN.

Gynecol Oncol. 2014 Jan;132(1):194-202. doi: 10.1016/j.ygyno.2013.11.010. Epub 2013 Nov 15.

6.

Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.

Blackham AU, Northrup SA, Willingham M, D'Agostino RB Jr, Lyles DS, Stewart JH 4th.

Surgery. 2013 Mar;153(3):333-43. doi: 10.1016/j.surg.2012.09.003. Epub 2012 Oct 25.

7.

VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1.

Schache P, Gürlevik E, Strüver N, Woller N, Malek N, Zender L, Manns M, Wirth T, Kühnel F, Kubicka S.

Gene Ther. 2009 Jul;16(7):849-61. doi: 10.1038/gt.2009.39. Epub 2009 Apr 16.

PMID:
19369968
8.

Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Westcott MM, Liu J, Rajani K, D'Agostino R Jr, Lyles DS, Porosnicu M.

J Virol. 2015 Aug;89(15):7944-54. doi: 10.1128/JVI.00757-15. Epub 2015 May 20.

9.

Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis.

Tumilasci VF, Olière S, Nguyên TL, Shamy A, Bell J, Hiscott J.

J Virol. 2008 Sep;82(17):8487-99. doi: 10.1128/JVI.00851-08. Epub 2008 Jun 25.

10.

Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.

Murphy AM, Besmer DM, Moerdyk-Schauwecker M, Moestl N, Ornelles DA, Mukherjee P, Grdzelishvili VZ.

J Virol. 2012 Mar;86(6):3073-87. doi: 10.1128/JVI.05640-11. Epub 2012 Jan 11. Erratum in: J Virol. 2013 Feb;87(3):1923.

11.

Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ.

Virology. 2013 Feb 5;436(1):221-34. doi: 10.1016/j.virol.2012.11.014. Epub 2012 Dec 14.

12.

VSV-tumor selective replication and protein translation.

Barber GN.

Oncogene. 2005 Nov 21;24(52):7710-9. Review.

PMID:
16299531
13.

Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.

Yarde DN, Nace RA, Russell SJ.

Exp Hematol. 2013 Dec;41(12):1038-49. doi: 10.1016/j.exphem.2013.09.005. Epub 2013 Sep 22.

14.
15.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG.

Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143.

16.

Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):140-9. doi: 10.1038/mt.2010.224. Epub 2010 Oct 26.

17.

Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.

Leveille S, Goulet ML, Lichty BD, Hiscott J.

J Virol. 2011 Dec;85(23):12160-9. doi: 10.1128/JVI.05703-11. Epub 2011 Sep 14.

18.

Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.

Patel MR, Jacobson BA, Ji Y, Drees J, Tang S, Xiong K, Wang H, Prigge JE, Dash AS, Kratzke AK, Mesev E, Etchison R, Federspiel MJ, Russell SJ, Kratzke RA.

Oncotarget. 2015 Oct 20;6(32):33165-77. doi: 10.18632/oncotarget.5320.

19.

VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):150-8. doi: 10.1038/mt.2010.225. Epub 2010 Oct 19.

20.

Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.

Felt SA, Moerdyk-Schauwecker MJ, Grdzelishvili VZ.

Virology. 2015 Jan 1;474:163-73. doi: 10.1016/j.virol.2014.10.026. Epub 2014 Nov 19.

Supplemental Content

Support Center